Reimagining Medicine

Company overview Financial review Conclusions Appendix References KisqaliⓇ continued strong momentum globally, with increasing recognition of its differentiated profile GROWTH Sales evolution USD m, % cc Ex-US US +66% 493 308 269 US MBC NBRx share1 Rolling 3 months, % 198 15% 224 110 Q2 2022 Q2 2023 May 2022 Consistent efficacy KISQALI Kisqali Ph3 OS results in 1L mBC2 34% Stage IV HR 95% CI MONALEESA-2 0.76 (0.63, 0.93) MONALEESA-7 0.76 (0.61, 0.96) May 2023 MONALEESA-3 0.67 (0.50, 0.90) Consistent benefit regardless of combination endocrine therapy, menopausal status, or site and number of metastases Included in NCCN guidelines³ as the only Category 1 treatment for 1L mBC with Al 1. Of CDK4/6 mBC market, US 3 months ending May 2023 from IQVIA Breast Cancer mBC metastatic breast cancer. NBRX-new to brand prescription. NCCN - national comprehensive cancer network. Al aromatase inhibitor. Market Sizing report. 2. MONALEESA-2: Hortobagyi et al, NEJM 2022; MONALEESA-7: Lu et al, Clin Cancer Res 2022; MONALEESA-3: Neven et al, ESMO Breast 2022. 3. NCCN Guidelines updated as of 27-Jan-2023. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. 8 Investor Relations | Q2 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation